# NCT07409272 (NCT07409272)

> A Study to Evaluate the Effectiveness and Safety of Setidegrasib, Given With Either mFOLFIRINOX or NALIRIFOX Chemotherapies, in People With Pancreatic Cancer

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT07409272
- Phase: PHASE3
- Status: RECRUITING
- Sponsor: Astellas Pharma Global Development, Inc.
- Conditions: Pancreatic Cancer; Metastatic Pancreatic Cancer; Metastatic Pancreatic Adenocarcinoma
- Interventions: Setidegrasib; Oxaliplatin; Leucovorin; Irinotecan; fluorouracil; liposomal irinotecan; Placebo
- Enrollment: 614
- Primary outcome: Overall Survival (OS)

## Preliminary discovery

Commentary in our index that names this trial so far. Final coverage is set when the report is built.

- X threads: 2
- Bluesky threads: 1

## Order

Focused, $750, price fixed at order: https://www.erudio.com/contact?report=nct07409272